CTLA4 and gastrointestinal stromal tumor: However in a clinical study of gastrointestinal stromal tumours (GIST), dasatinib and anti‐CTLA4 antibody ipilimumab were well tolerated yet the combination was not synergistic, potentially due to the lack of a biomarker‐driven approach 165.